US · Healthcare · Biotechnology
EPS came in at -1.87 against a street estimate of -2.03 — a beat of 7.9%.
Analysts rate NextCure Inc a buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $20.00.
| Fund | Stake |
|---|---|
| Squadron Capital Management LLC | 7.34% |
| Affinity Asset Advisors, LLC | 6.69% |
| Ikarian Capital, LLC | 6.60% |
| Sofinnova Ventures | 6.16% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 4.87% |
| Vanguard Capital Management, LLC | 4.44% |
| Pfizer Inc | 4.25% |
| Opaleye Management Inc | 3.91% |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for NextCure Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.